Related Experiment Videos
A one-year study on the pharmacodynamic profile of interferon-beta1a in MS
F Bagnato1, C Pozzilli, C Scagnolari
1Department of Neurological Sciences, University La Sapienza, Rome, Italy. francesca.bagnato@uniroma1.it
Neurology
|May 16, 2002
Abstract:
Interferon (IFN)-beta1a induction of neopterin and beta2-microglobulin (beta2-MG) were evaluated over 1 year in patients with MS. Neopterin and beta2-MG levels peaked 24 to 48 hours after weekly injections of IFNbeta1a over the entire study period. Predose levels of neopterin decreased significantly, consistent with a long-term decrease in IFNgamma expression and macrophage activation during IFNbeta-1a treatment. Predose levels of beta2-MG increased, the significance of which is as yet unclear.